Smart Inhalers Market Size, Share & Trends Analysis Report By Type (Dry Powdered Inhalers, Metered Dose Inhalers), By Indication (Asthma, COPD), By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global smart inhalers market size was valued at USD 10.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 19.3% from 2022 to 2030. The rising prevalence of chronic respiratory diseases (CRDs) worldwide and the availability of better clinical outcomes are expected to contribute to the industry growth. According to the WHO, around 262 million people globally suffered from asthma in 2019, which is a major non-communicable disease that affects both adults and children. In addition, chronic obstructive pulmonary disease (COPD) was responsible for about 3.23 million deaths in the same year.The Covid-19 pandemic affected the supply chain in all industries globally. Several industries witnessed a shortage of product inventories, and it also increased the difficulty of clinical testing, regulatory processes, and post-approval activities during the pandemic. However, it is anticipated that the market will grow in the post-pandemic period as healthcare providers are switching to connected medical devices to ensure that patients receive the best treatment and consultation possible, regardless of the situation.

In addition, COVID-19 has prompted an increase in the demand for cutting-edge digital devices and solutions for respiratory and pulmonary care, which is, in turn, driving the demand for smart inhalers. For instance, in April 2020, Adherium Limited and Planet Innovation announced a strategic partnership for the development of hardware and software for respiratory devices. This partnership was expected to strengthen Adherium's presence in both the asthma and COPD management market by offering sensors created to provide the physiological data necessary to facilitate patient monitoring by the physicians.

The increasing focus on the development of smart inhalers and a rise in initiatives by key market players for R&D efforts are driving the demand for smart inhalers. In addition, more companies are integrating digital technologies into their product offerings to enhance the effectiveness of medication and the management of asthma and COPD. For instance, in April 2022, Aptar Pharma, a key market player, introduced HeroTracker Sense, a novel digital chronic respiratory e-health solution that converts a traditional metered dose inhaler into a smart inhaler.

Furthermore, the latest research has indicated that the adoption of smart inhalers is most likely to provide patients with an easier way to maintain treatment adherence and control symptoms. For instance, a 2020 Cleveland Clinic study discovered that patients with COPD using Propeller company’s smart inhalers had a noticeably lower risk of being admitted to the hospital, with a nearly 35% drop in visits compared to the prior year.

Type Insights

In 2021, the MDIs segment captured a dominant share of over 60.0%. MDIs are gaining popularity as they are efficient and easy to use in a short burst of sprays of a fixed dose, which is typically administered by the patient themselves through inhalation. In September 2022, the U.K.-based research lab OzUK Limited and H&T Presspart partnered to bring generic MDIs for conventional Asthma/COPD applications into the market for H&T Presspart's customers. Based on type, the market is segmented into dry powdered inhalers (DPIs) and metered dose inhalers (MDIs).

The dry powdered inhalers (DPIs) segment is expected to register the fastest CAGR of 18.6% over the forecast period. Due to growing concerns over the environmental impact of inhaler devices that use chloroflouro carbons as propellants, DPIs are now preferred over pressurized MDIs as well as nebulizers as a treatment for respiratory illnesses.

Indication Insights

In 2021, the COPD segment held the largest revenue share of over 50.0% pertaining to the higher prevalence of COPD globally. According to the WHO, around 3.23 million fatalities attributed to COPD occurred in 2019. Based on indication, the market is segmented into asthma, COPD, and others.

The asthma segment is anticipated to grow at a rate of

18.3% over the forecast period due to the rise in hospitalizations for asthma, particularly in young children. According to the WHO, approximately 300 million people globally are currently suffering from asthma, and the prevalence of the condition is increasing by 50% every ten years.

Distribution Channel Insights

The hospital pharmacies segment accounted for the largest share of over 40.0% in 2021. The growing geriatric population and rising incidence of CRDs are contributing to the industry growth. The geriatric population is often hospitalized for a variety of chronic respiratory illnesses, and they consider purchasing medication from hospital pharmacies. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment is anticipated to grow at the fastest rate of 19.2% over the forecast period. Due to comfort, flexibility, and convenience, retail pharmacies are preferred more by the customers, and this trend is driving up the demand for retail pharmacies in the market. The quick expansion and modernization of existing pharmacies to increase market penetration are favorably influencing industry growth.

End-use Insights

In 2021, hospitals accounted for the largest share of over 50.0%. Expanding public-private partnerships, rapid advancements in healthcare infrastructure and better access to healthcare services are all expected to have a significant impact on the hospitals segment. Based on end-use, the market for smart inhalers is segmented into hospitals, home care settings, and others.

The home care settings segment is anticipated to grow at the fastest rate of 20.2% over the forecast period. Due to the rising cost of healthcare, many people with CRDs prefer to receive treatment at home. In addition, the growing preference for home care by elderly patients is expected to fuel the segment's growth.

Regional Insights

In 2021, North America held the largest share of over 45.0%. The high prevalence of COPD and asthma in the U.S. and Canada is contributing to the market growth. In addition, 10% of people in North America suffer from asthma and it affects over 25 million people in the U.S. In September 2021, Adherium Limited, a key player in the respiratory eHealth, remote monitoring announced that the U.S. FDA 510(k) has approved its Hailie Sensor, which includes physiological measures for tracking the use of asthma and COPD medications for sale in the U.S. region.

Asia Pacific is expected to expand at the fastest growth rate of 21.2% during the forecast period due to the growing elderly population, the incidence of CRDs, expanding healthcare infrastructure, and rising government initiatives. According to the National Statistical Office Elderly in India 2021 report, India's elderly population (those 60 and older) is expected to grow by 41% over the course of a decade, from 138 million in 2021 to 194 million in 2031.

Key Companies & Market Share Insights

Players operating in the market are increasingly focusing on acquisitions, mergers, partnerships, and expansion to strengthen their market presence. For example, in August 2022, Adherium Limited, a key market player in respiratory eHealth & data management solutions and remote monitoring, announced a partnership with Trudell Medical Limited to serve COPD patients in the U.S. Through this partnership, both companies will evaluate COPD patients after they are discharged from the hospital using the Trudell's U.S. operation, Monaghan Medical, and its subsidiary Aetonix's aTouchAway platform combined with Adherium's Hailie sensors with the goal of reducing readmissions and enhancing patient outcomes. Some prominent players in the global smart inhalers market include:

• H&T Presspart Manufacturing Ltd.

• Personal Air Quality Systems Private Limited

• COHERO Health Inc.

• Cognita Labs

• Adherium Limited

• Amiko Digital Health Limited

• Teva Pharmaceuticals Industries Ltd.

• Propeller Health

• Novartis AG

• Pneuma Respiratory Inc.

• 3M Health Care Limited

• AireHealth, Inc.

• FindAir Sp. z o.o

Smart Inhalers Market Report Scope

Global Smart Inhalers Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global smart inhalers market report based on type, indication, distribution channel, end-use, and region:

• Type Outlook (Revenue, USD Million, 2017 - 2030)

  • Dry Powdered Inhalers (DPIs)

  • Metered Dose Inhalers (MDIs)

• Indication Outlook (Revenue, USD Million, 2017 - 2030)

  • Asthma

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Other

• Distribution Channel Outlook (Revenue, USD Million, 2017 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• End-use Outlook (Revenue, USD Million, 2017 - 2030)

  • Hospitals

  • Homecare Settings

  • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE